Drugs / lumefantrine
lumefantrine
also known as
Benflumelol · Benflumetol · CPG-56695 · Dl-benflumelol · GNF-PF-1971 · lumefantrina · Lumefantrine component of coartem · lumefantrine-SDF · +1 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | COARTEM | — | 2009-04-07 | fda.gov ↗ |
Trials 61 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT05330273 | Apr → Nov 2022 | malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT05236530 | Mar → Oct 2022 | malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT05084651 | Nov 2021 → May 2022 | malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02242799 | Jun 2015 → Sep 2016 | HIV infectious disease, malaria | University of Liverpool | Completed | No outcome recorded |
| Phase 1 | NCT02184637 | Jul 2014 → Apr 2015 | Plasmodium vivax malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01876966 | Mar → Jul 2011 | HIV infectious disease | Janssen Pharmaceutica N.V., Belgium | Completed | No outcome recorded |
| Phase 1 | NCT00697892 | Jul 2005 → Dec 2008 | HIV infectious disease, malaria | Fran Aweeka | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05550909 | Oct → Dec 2022 | Plasmodium falciparum malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 2 | NCT04546633 | Feb 2021 → Aug 2024 | Plasmodium falciparum malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03167242 | Aug 2017 → Jun 2021 | Plasmodium falciparum malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01614964 | Aug 2013 → Jan 2016 | Plasmodium falciparum malaria | Tulane University | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05764746 | May 2023 → Dec 2024 | Plasmodium falciparum malaria | Muhimbili University of Health and Allied Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT04300309 | Dec 2020 → Jul 2023 | Plasmodium falciparum malaria | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 313 trials | ||||||
| Phase 3 | NCT05951595 | Sep 2025 → Jul 2026 overdue | Plasmodium falciparum malaria | University of Oxford | Recruiting | No outcome recorded |
| Phase 3 | NCT05842954 | Mar 2024 → Jun 2025 | Plasmodium falciparum malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03355664 | Mar 2018 → Mar 2020 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT02610400 | Feb 2016 → Dec 2017 | malaria | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT01939886 | Apr → Nov 2013 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT01374581 | May 2012 → Jun 2014 | malaria | University of Antwerp | Completed | No outcome recorded |
| Phase 3 | NCT01625871 | Sep 2011 → Sep 2012 | Plasmodium vivax malaria | University of Khartoum | Completed | No outcome recorded |
| Phase 3 | NCT00393679 | Jul 2007 → Dec 2009 | malaria | Institute of Tropical Medicine, Belgium | Completed | No outcome recorded |
| Phase 3 | NCT00484900 | May 2006 → May 2007 | Plasmodium falciparum malaria | Dafra Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00123552 | Nov 2004 → Jun 2006 | malaria | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT00406146 | Oct 2004 → Dec 2006 | malaria | University of Ghana Medical School | Unknown | No outcome recorded |
| Phase 3 | NCT00118794 | Sep 2004 → Jun 2005 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT00709969 | Jul 2002 → Feb 2003 | Plasmodium falciparum malaria | Novartis | Completed | No outcome recorded |
| Phase 425 trials | ||||||
| Phase 4 | NCT07713602 | Jun 2027 → May 2028 expected | malaria | Novartis Pharmaceuticals | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07403643 | Apr → Dec 2026 expected | malaria | Curtin University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06967519 | Dec 2025 → Dec 2027 expected | HIV infectious disease, malaria | Yale University | Recruiting | No outcome recorded |
| Phase 4 | NCT06424002 | Jun → Dec 2024 | Plasmodium falciparum malaria | Kamuzu University of Health Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT05788094 | Jun 2023 → Feb 2026 overdue | Plasmodium vivax malaria | Shoklo Malaria Research Unit | Recruiting | No outcome recorded |
| Phase 4 | NCT04618523 | Oct 2020 → Feb 2022 | malaria | Ministry of Public Health, Democratic Republic of the Congo | Completed | No outcome recorded |
| Phase 4 | NCT05070520 | Sep 2020 | Plasmodium falciparum malaria | National Malaria Control Program, Niger | Completed | No outcome recorded |
| Phase 4 | NCT03453840 | Feb 2018 → Aug 2021 | Plasmodium falciparum malaria | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT03241901 | Jul → Dec 2017 | Plasmodium falciparum malaria | Muhimbili University of Health and Allied Sciences | Completed | No outcome recorded |
| Phase 4 | NCT02940756 | Mar 2017 → Jan 2018 | malaria | Ministry of Public Health, Democratic Republic of the Congo | Completed | No outcome recorded |
| Phase 4 | NCT02742285 | May → Jul 2016 | malaria | Thierry Buclin | Completed | No outcome recorded |
| Phase 4 | NCT01697787 | Oct 2012 → Sep 2014 | Plasmodium falciparum malaria | Centre Muraz | Completed | No outcome recorded |
| Phase 4 | NCT01651416 | Jul → Dec 2012 | anemia, malaria | Centre for Global Health Research, Ghana | Completed | No outcome recorded |
| Phase 4 | NCT01599000 | Mar 2011 → Jul 2012 | malaria | Papua New Guinea Institute of Medical Research | Completed | No outcome recorded |
| Phase 4 | NCT01038063 | Oct 2010 → Sep 2013 | malaria | Liverpool School of Tropical Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT00869700 | Jun 2009 → Feb 2010 | HIV infectious disease, malaria | University of Cape Town | Completed | No outcome recorded |
| Phase 4 | NCT00902811 | Dec 2008 → Oct 2009 | Plasmodium falciparum malaria | Medecins Sans Frontieres, Netherlands | Unknown | No outcome recorded |
| Phase 4 | NCT00790881 | Oct 2008 → Aug 2009 | HIV infectious disease, malaria | University of Cape Town | Completed | No outcome recorded |
| Phase 4 | NCT00620438 | Feb 2008 → Jul 2011 | HIV infectious disease, tuberculosis | Makerere University | Unknown | No outcome recorded |
| Phase 4 | NCT00619944 | Feb → Dec 2008 | HIV infectious disease | Makerere University | Completed | No outcome recorded |
| Phase 4 | NCT00444106 | May 2007 → Nov 2008 | Plasmodium falciparum malaria | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00374205 | Sep 2006 → Oct 2007 | Plasmodium falciparum malaria | Bernhard Nocht Institute for Tropical Medicine | Terminated | No outcome recorded |
| Phase 4 | NCT00164710 | Apr → Sep 2005 | Plasmodium falciparum malaria | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT00140361 | Jan 2000 → Jan 2008 | malaria | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT00451139 | — | malaria | Jimma University | Completed | No outcome recorded |
| Phase not applicable10 trials | ||||||
| — | NCT07527182 | May 2024 → Oct 2025 | Plasmodium falciparum malaria | Didier Menard | Completed | No outcome recorded |
| — | NCT06970600 | Mar → Oct 2024 | Plasmodium falciparum malaria | Manhiça Health Research Centre | Completed | No outcome recorded |
| — | NCT05540470 | Sep 2022 → Mar 2025 | Plasmodium vivax malaria | Cayenne Hospital | Completed | No outcome recorded |
| — | NCT02600767 | Dec 2015 → May 2016 | malaria | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| — | NCT01575613 | Apr → Nov 2012 | malaria | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT01326754 | Aug 2011 → Jun 2012 | Plasmodium falciparum malaria | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| — | NCT00725777 | Jul 2008 → Dec 2011 | malaria | Albert Schweitzer Hospital | Completed | No outcome recorded |
| — | NCT00157833 | Jul 2004 → Aug 2005 | Plasmodium falciparum malaria, Plasmodium vivax malaria | Menzies School of Health Research | Completed | No outcome recorded |
| — | NCT00229775 | Jul 2003 → Jul 2008 | malaria | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| — | NCT00304980 | Mar 2003 → Apr 2005 | Plasmodium falciparum malaria | Institute of Tropical Medicine, Belgium | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 63 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06294912 Background | Apr 2024 → Jan 2025 | malaria | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT04310085 Background | Feb → Dec 2020 | Plasmodium falciparum malaria, parasitemia | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT03510481 Background | May 2018 → Nov 2019 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02223871 Background | Jun → Jul 2014 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00266058 Comparator | Dec 2005 → Nov 2010 | HIV infectious disease, malaria | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04280692 Background | Aug 2022 → Dec 2025 | Plasmodium falciparum malaria | University of Oxford | Suspended | No outcome recorded |
| Phase 1/2 | NCT01603251 Comparator | Jan → Apr 2013 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT07559370 Comparator | Jan 2026 → Jun 2027 expected | Plasmodium falciparum malaria | Victoria Biomedical Research Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT07235033 Comparator | Jan 2024 → Mar 2025 | Plasmodium falciparum malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT04675931 Background | Mar 2022 → Jul 2025 | Plasmodium falciparum malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT04661579 Background | Nov 2020 → Jun 2022 | Plasmodium falciparum malaria | PATH | Completed | No outcome recorded |
| Phase 2 | NCT04020653 Background | Sep 2019 → May 2020 | malaria | Neopharma Japan Co., Ltd. | Withdrawn | No outcome recorded |
| Phase 2 | NCT03199755 Comparator | Aug → Dec 2018 | malaria | Worcester Polytechnic Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT04264130 Comparator | Jul 2018 → Dec 2019 | urinary schistosomiasis | Centre de Recherche Médicale de Lambaréné | Completed | No outcome recorded |
| Phase 2 | NCT02696928 Background | Apr 2016 → Oct 2017 | Plasmodium vivax malaria | Heidelberg University | Withdrawn | No outcome recorded |
| Phase 2 | NCT01445938 Comparator | Oct 2011 → Jan 2012 | malaria | Sanofi | Terminated | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT04009343 Comparator | Jun 2019 → Aug 2020 overdue | Plasmodium falciparum malaria | Johns Hopkins Bloomberg School of Public Health | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT02453308 Comparator | Aug 2015 → Mar 2018 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 2/3 | NCT01935882 Comparator | Sep 2013 → Jul 2015 | Plasmodium falciparum malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 315 trials | ||||||
| Phase 3 | NCT06962319 Comparator | Sep 2025 → Aug 2028 expected | malaria | Liverpool School of Tropical Medicine | Recruiting | No outcome recorded |
| Phase 3 | NCT06516042 Comparator | Aug 2024 → Jan 2025 overdue | Plasmodium falciparum malaria | PATH | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04695197 Comparator | Jan 2021 → Nov 2022 | COVID-19, malaria | Liverpool School of Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT03923725 Comparator | Sep 2020 → Mar 2024 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT03452475 Comparator | Mar 2018 → Jun 2019 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT02348788 Comparator | Jan 2015 → Dec 2017 | Plasmodium vivax malaria | Menzies School of Health Research | Unknown | No outcome recorded |
| Phase 3 | NCT01899820 Comparator | Apr 2013 → Jun 2014 | malaria | Sabah Ahmed Omar | Unknown | No outcome recorded |
| Phase 3 | NCT02974348 Comparator | Jan → May 2013 | Plasmodium falciparum malaria | University of Bamenda | Completed | No outcome recorded |
| Phase 3 | NCT01152931 Comparator | Aug → Nov 2010 | malaria | University of Lagos, Nigeria | Completed | No outcome recorded |
| Phase 3 | NCT01082705 Comparator | Apr 2010 → Jun 2011 | Plasmodium falciparum malaria | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 3 | NCT01845701 Comparator | Mar 2010 → Apr 2014 | malaria | University of Yaounde 1 | Completed | No outcome recorded |
| Phase 3 | NCT01054248 Comparator | Feb 2010 → Sep 2016 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT00694694 Comparator | Jun → Dec 2008 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT00541385 Comparator | Oct 2007 → Sep 2008 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 3 | NCT00297882 Comparator | Jul 2006 → Apr 2009 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 422 trials | ||||||
| Phase 4 | NCT06347471 Comparator | May 2024 → Nov 2025 | Plasmodium falciparum malaria | Infectious Diseases Research Collaboration, Uganda | Completed | No outcome recorded |
| Phase 4 | NCT06300970 Comparator | Aug 2022 → Aug 2023 | Plasmodium falciparum malaria | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT05605925 Background | Aug → Dec 2022 | malaria | Makerere University | Unknown | No outcome recorded |
| Phase 4 | NCT05340153 Comparator | Apr → Dec 2022 | malaria | University of Yaounde 1 | Unknown | No outcome recorded |
| Phase 4 | NCT05343312 Comparator | Mar 2022 → Sep 2023 | Plasmodium falciparum malaria | Manhiça Health Research Centre | Completed | No outcome recorded |
| Phase 4 | NCT04829695 Comparator | Apr → Dec 2021 | Plasmodium falciparum malaria | University of Yaounde 1 | Unknown | No outcome recorded |
| Phase 4 | NCT04767191 Comparator | Mar 2021 → Dec 2022 | malaria | Jhpiego | Completed | No outcome recorded |
| Phase 4 | NCT04565184 Comparator | May 2019 → Nov 2020 | Plasmodium falciparum malaria | University of Yaounde 1 | Completed | No outcome recorded |
| Phase 4 | NCT04370977 Comparator | Mar → Sep 2018 | malaria | Manhiça Health Research Centre | Completed | No outcome recorded |
| Phase 4 | NCT02325180 Comparator | Jan → Jun 2015 | Plasmodium falciparum malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 4 | NCT02741024 Comparator | Oct 2013 → Dec 2014 | malaria | Medecins Sans Frontieres, Netherlands | Completed | No outcome recorded |
| Phase 4 | NCT01704508 Comparator | Nov 2012 → Oct 2015 | Plasmodium falciparum malaria | Bandim Health Project | Completed | No outcome recorded |
| Phase 4 | NCT01998295 Comparator | May → Jun 2012 | — | Muhimbili University of Health and Allied Sciences | Completed | No outcome recorded |
| Phase 4 | NCT02168569 Comparator | Jun 2011 → Jan 2012 | Plasmodium falciparum malaria | Manhiça Health Research Centre | Completed | No outcome recorded |
| Phase 4 | NCT01082731 Comparator | Nov 2010 → Jan 2012 | malaria | Centers for Disease Control and Prevention | Terminated | No outcome recorded |
| Phase 4 | NCT04877626 Comparator | Sep 2008 → Oct 2009 | Plasmodium falciparum malaria | National University of Colombia | Completed | No outcome recorded |
| Phase 4 | NCT00699920 Comparator | Jun 2008 → Jun 2010 | malaria | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00540410 Comparator | Sep 2007 → Feb 2009 | Plasmodium falciparum malaria | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00529867 Comparator | May → Dec 2007 | Plasmodium falciparum malaria | Dafra Pharma | Completed | No outcome recorded |
| Phase 4 | NCT00495508 Comparator | Oct 2006 → Jun 2009 | Plasmodium falciparum malaria | Epicentre | Completed | No outcome recorded |
| Phase 4 | NCT00452907 Comparator | Jul 2005 → Jun 2007 | malaria | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT03768908 Comparator | Jan → Jul 2005 | Plasmodium falciparum malaria | Professor Anders Björkman | Completed | No outcome recorded |
| Phase not applicable7 trials | ||||||
| — | NCT07533136 Comparator | May 2026 → Oct 2028 expected | Plasmodium vivax malaria | Walter Reed Army Institute of Research (WRAIR) | Not yet recruiting | No outcome recorded |
| — | NCT03813108 Background | Apr 2019 → Feb 2021 | Plasmodium falciparum malaria | Radboud University Medical Center | Terminated | No outcome recorded |
| — | NCT01967472 Comparator | Sep → Dec 2013 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| — | NCT00720811 Comparator | Oct 2009 → Jan 2012 | malaria, pneumonia | Mbarara University of Science and Technology | Completed | No outcome recorded |
| — | NCT00868465 Comparator | Apr 2009 → May 2010 | malaria | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT01567423 Comparator | Apr 2008 → Apr 2009 | Plasmodium falciparum malaria | Epicentre | Completed | No outcome recorded |
| — | NCT00460369 Comparator | Apr → Nov 2007 | malaria | Research Institute for Development | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-11-23 | Novartis Pharmaceuticals | Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria novartis.com ↗ |
| 2021-09-29 | Novartis Pharmaceuticals | Novartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria novartis.com ↗ |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 125 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lumefantrine | “Patients with uncomplicated falciparum malaria and over six months of age were recruited in Cameroon, Mali, Rwanda and Sudan. 1,384 patients were randomly assigned to receive...” PMID 19366448 ↗ Apr 2009122“RACD involved rapid diagnostic testing and treatment with artemether-lumefantrine and single-dose primaquine, rfMDA involved presumptive treatment with artemether-lumefantrine,...” PMID 32334702 ↗ Apr 2020 “Subjects will be immunized 3 times by exposure to the bites of P. falciparum NF135.C10 infected mosquitoes and receive presumptive treatment with artemether/lumefantrine...” NCT03813108 ↗ “Our aim was to compare the safety and efficacy of dihydroartemisinin-piperaquine with that of artemether-lumefantrine in patients with uncomplicated malaria caused by...” PMID 17336652 ↗ Mar 2007 “Participants that provide consent to participate in the TDA and are deemed eligible for treatment will receive a course of dihydroartemisinin-piperaquine (DP) if male, and...” NCT06516042 ↗ “Patients will be treated with single dose SP (25 mg/kg of the sulfadoxine component in a single dose) plus CQ (25 mg/kg over three days) or artemether + lumefantrine (twice...” NCT00229775 ↗ “Coartem®: artemether 20 mg - lumefantrine 120 mg co-formulated tabs (Coartem®, Novartis) given as six twice-daily doses over three days, according to weight-groups.” NCT00902811 ↗ “Augmented 4 day regimen of artemether lumefantrine 2 doses per day for 4 days. Each dose consists of 5 tablets (20/120 mg of artemether/lumefantrine per tablet).” NCT01054248 ↗ “Artemether 80 mg + lumefantrine 480 mg was administered twice a day for 3 days with a standard meal or drink rich in fat within 30 min of dosing, as per label.” NCT07235033 ↗ “KLU156, a fixed dose combination of ganaplacide (KAF156) and a solid dispersion formulation of lumefantrine (lumefantrine-SDF)” NCT05842954 ↗ “artemether 20 mg / lumefantrine 120 mg co-formulated tablets given as six twice-daily doses over three days” NCT01567423 ↗ “Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight” NCT03355664 ↗ “A blister of 24 tablets of Artemether 20 mg + lumefantrine 120 mg of generic medication” NCT05540470 ↗ “80 mg of oral artemether and 480 mg of oral lumefantrine twice daily for 3 days” PMID 28916443 ↗ Sep 2017 “a solid dispersion formulation of lumefantrine (LUM-SDF) in pediatric patients” NCT04546633 ↗ “A single Coartem tablet contains 20 mg artemether and 120 mg lumefantrine.” NCT03199755 ↗ “artemether-lumefantrine for repeated treatment of uncomplicated malaria in” PMID 25436614 ↗ Dec 2014 “one tablet (20mg artemether and 120mg lumefantrine)” NCT05343312 ↗ “Artemether 20 mg and lumefantrine 120 mg” NCT04020653 ↗ “Artemether-lumefantrine for 3 days” NCT02453308 ↗ “Artemether: Lumefantrine” NCT07713602 ↗ “Lumefantrine” NCT04675931 ↗ |
| Known as | Benflumelol | ChEMBL registry synonym — accepted as the source's own label CHEMBL38827 ↗ |
| Known as | Benflumetol | ChEMBL registry synonym — accepted as the source's own label CHEMBL38827 ↗ |
| Known as | CPG-56695 | ChEMBL registry synonym — accepted as the source's own label CHEMBL38827 ↗ |
| Known as | Dl-benflumelol | ChEMBL registry synonym — accepted as the source's own label CHEMBL38827 ↗ |
| Known as | GNF-PF-1971 | ChEMBL registry synonym — accepted as the source's own label CHEMBL38827 ↗ |
| Known as | lumefantrina | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04877626 ↗ |
| Known as | Lumefantrine component of coartem | ChEMBL registry synonym — accepted as the source's own label CHEMBL38827 ↗ |
| Known as | lumefantrine-SDF | “KLU156, a fixed dose combination of ganaplacide (KAF156) and a solid dispersion formulation of lumefantrine (lumefantrine-SDF)” NCT05842954 ↗ |
| Known as | Lumefantrinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL38827 ↗ |
| Modality | Small molecule | “Lumefantrine is a synthetic compound” NCT00620438 ↗ |
| Route | Oral | “Artemether-lumefantrine (Coartem) tablets containing 20 mg artemether and 120 mg lumefantrine twice a day for 3 days, dosage dependent on body weight.” NCT00444106 ↗ |